Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors
Papulopustular rash (PPR) is the most frequent cutaneous adverse event during treatment with epidermal growth factor receptor inhibitors (EGFRis). Although often mild in severity, it can impair patients’ quality of life and may also be a reason for discontinuing or changing the dose of the antineopl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2024-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2024/8859032 |